Quanergy Selected by PARIFEX as Exclusive Supplier of Long-Range 3D LiDAR for Highway Speed Detection and Enforcement
13.7.2021 13:00:00 EEST | Business Wire | Press release
Quanergy Systems, Inc., a leading provider of OPA-based solid state LiDAR sensors and smart 3D solutions for automotive and IoT, today announced that it has expanded its exclusive agreement with PARIFEX, a leading solution provider in project management for speed enforcement and smart cities, to deploy Quanergy’s M-Series 3D-LiDAR sensors for highway speed monitoring and enforcement. The new project will be deployed with the French Ministry of Interior, with future expansion to global projects.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005506/en/
Quanergy Selected by PARIFEX as Exclusive Supplier of Long-Range 3D LiDAR for Highway Speed Detection and Enforcement (Graphic: Business Wire)
The M8 LiDAR sensor from Quanergy features an extended range up to 200 meters and a superior angular beam resolution of 0.033 degrees, enabling highly accurate and reliable detection of speeding violations even in busy, fast-paced highway environments. The sensor will be integrated exclusively into the VIGIE Double-Side solutions by PARIFEX, an extra-urban speed control system able to track, identify and classify different vehicles simultaneously on different lanes and identify the speeding one through a picture of the front and the rear of the vehicle.
PARIFEX offers the only approved LiDAR-based system for speed measurement and control in France. Building on a multi-year partnership, this project will accelerate the goal of achieving safer highway systems.
“We have been committed to providing innovative and reliable solutions for many years to take part in the improvement of road safety, especially on fast highways,” said Franck Peyré, CEO at PARIFEX, “We chose Quanergy’s LiDAR for its accuracy to strengthen the VIGIE Double-Side solution, long-range detection at high speeds, as well as its high performance in challenging conditions. Our first project with Quanergy, which was deployed in Rouen France, confirmed our decision to continue leveraging Quanergy’s LiDAR technology in the VIGIE Double-Side.”
The fully automated, LiDAR-based VIGIE Double-Side monitors multiple lanes of traffic to detect, classify, and identify vehicles exceeding posted speed limits. This solution simultaneously measures the speed of all vehicles, and it can identify an offending vehicle from hundreds of meters upstream. The solution automatically classifies the category of vehicle (truck, passenger car, motorcycle, etc.) and adapts the speed threshold accordingly.
“From our first deployment in 2017, Quanergy and PARIFEX have worked together to leverage 3D LiDAR technology to make the world a safer place--one highway at a time,” said Enzo Signore, CMO at Quanergy, “This continuous deployment with PARIFEX is an important step towards a future with fewer road accidents.”
For more information, visit www.quanergy.com
About Quanergy Systems, Inc.
Quanergy Systems’ mission is to create powerful, affordable smart LiDAR solutions for automotive and IoT applications to enhance people’s experiences and safety. Quanergy has developed the only true 100% solid state CMOS LiDAR sensor built on optical phased array (OPA) technology to enable the mass production of low-cost, highly reliable 3D LiDAR solutions. Through Quanergy’s smart LiDAR solutions, businesses can now leverage real-time, advanced 3D insights to transform their operations in a variety of industries including industrial automation, physical security, smart cities, smart spaces, and much more. Quanergy solutions are deployed by over 350 customers across the globe. For more information, please visit us at www.quanergy.com.
About PARIFEX
PARIFEX is a leading solution provider in project management, helping its clients in all fields of activity in the conception, management, development, and integration of their great engineering projects in industry and road safety. Through its expertise, the company also designs leading solutions for projects such as smart cities, new mobility, and more. PARIFEX was founded in 1994 and has branches in Europe and Asia, along with clients throughout the world. For more information, visit www.parifex.com/en.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005506/en/
Contact information
Quanergy Media Contact
Neal Stein
Media@quanergy.com
PARIFEX Media Contact
Mélissa Guimaraes
mguimaraes@parifex.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 14:30:00 EEST | Press release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom